ClinicalTrials.gg
CompletedNCT06176196Updated Oct 1, 2025

Evaluation of Efficacy and Safety of VX-548 for Painful Lumbosacral Radiculopathy (PLSR)

A Phase 2 interventional study of VX-548 and Placebo in Painful Lumbosacral Radiculopathy, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 54 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-10-01.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2024, 2 years 1 month ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Sep 2025.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
218
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 126 studies in Radiculopathy with a site in United States — 29 open to participants now, 37 under way, 2 of them phase 3. Radiculopathy · United States.

Enrollment
18th of 106
218 · median 78
Started
2023
with 4 others
Phase 2
10 of 126
none open now
Registered
111th of 126
by date

Among the 126 studies in Radiculopathy with a site in United States, this one is the 18th largest by enrollment of the 106 interventional ones that give a count, is one of 5 that started in 2023, is one of 10 in phase 2, and was the 111th registered.

Radiculopathy

484 studies on the registry are indexed under Radiculopathy; 144 are open to participants now.

Browse Radiculopathy studies →

Open to participants now

29 of the 126 studies in Radiculopathy with a site in United States are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 79 Radiculopathy studies recruiting now, 23 (29%) set no upper age limit and 48 (61%) stop at 75 or younger; 3 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 126 studies in Radiculopathy with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the efficacy and safety of VX-548 in treating participants with PLSR.

03

Conditions studied

  • Painful Lumbosacral Radiculopathy

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Body weight greater than or equal to (>=)45 kilogram (kg)
  • (BMI) less than or equal to (\<=) 40 kg/ meter square (m\^2)
  • Diagnosis of PLSR for greater than (>)3 months as per criteria pre-specified in the protocol
  • Weekly average of daily NPRS score >=4 and \<10 with limited variation in the 7-day Run-in Period

Key Exclusion Criteria:

  • More than 3 missing daily NPRS scores during the 7-day Run-in Period
  • Moderate or severe painful neuropathy other than PLSR as pre-specified in the protocol
  • History of prior lumbar spine surgery (e.g., discectomies, laminectomies, foraminotomies, or fusion)

Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
218 participants (actual)

Study arms

  • Experimental
    VX-548

    Participants will receive VX-548 up to 12 weeks.

    Drug: VX-548

  • Placebo comparator
    Placebo

    Participants will receive placebo matched to VX-548 up to 12 weeks.

    Drug: Placebo

Interventions

  • DrugVX-548

    Tablets for oral administration.

    Also known as: Suzetrigine

  • DrugPlacebo

    Tablets for oral administration.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Weekly Average of Daily leg Pain Intensity on a Numeric Pain Rating Scale (NPRS)

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Change From Baseline in the Weekly Average of the Daily Sleep Interference Scale (DSIS)

    Time frame: Baseline, Week 12

  2. Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: From Day 1 up to Week 14

07

Study locations

54 sites
  • Hope Research Institute
    Phoenix, Arizona 85018, United States
  • Arizona Research Center
    Phoenix, Arizona 85053, United States
  • Trovare Clinical Research
    Bakersfield, California 93301, United States
  • Velocity Clinical Research - Banning
    Banning, California 92220, United States
  • Velocity Clinical Research - San Diego
    La Mesa, California 91942, United States
  • Probe Clinical Research
    Riverside, California 92501, United States
  • Pain Management and Injury Relief
    Thousand Oaks, California 91320, United States
  • Visionary Investigators Network
    Aventura, Florida 33180, United States
  • Nature Coast Clinical Research - Crystal River
    Crystal River, Florida 34429, United States
  • JY Research Institute
    Cutler Bay, Florida 33189, United States
  • Fleming Island Center for Clinical Research
    Fleming Island, Florida 32003, United States
  • Convenient Medical Research
    Hialeah, Florida 33013, United States
  • Jacksonville Center for Clinical Research
    Jacksonville, Florida 32216, United States
  • L&C Professional Medical Research Institute
    Miami, Florida 33144, United States
  • Medical Research of Westchester
    Miami, Florida 33165, United States
  • ARSN-Brain and Spine Institute
    Port Orange, Florida 32127, United States
  • Accel Research Site - St. Petersburg/Largo
    Seminole, Florida 33777, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30331, United States
  • ClinCept Clinical Research
    Columbus, Georgia 31904, United States
  • Accel Research Sites - Neurostudies
    Decatur, Georgia 30030, United States
  • Velocity Clinical Research - Savannah Neurology Specialists
    Savannah, Georgia 31406, United States
  • Velocity Clinical Research - Savannah
    Savannah, Georgia 31406, United States
  • Center for Pain Management and Rehab
    Stockbridge, Georgia 30281, United States
  • Velocity Clinical Research - Boise
    Meridian, Idaho 83642, United States
  • Healthcare Research Network II, LLC
    Flossmoor, Illinois 60422, United States
  • Essential Concepts Research Solutions
    Palos Hills, Illinois 60465, United States
  • AMR Wichita East, KS
    Wichita, Kansas 67207, United States
  • Velocity Clinical Research - Rockville
    Rockville, Maryland 20854, United States
  • Brigham and Women's Hospital (BWH)
    Boston, Massachusetts 02115, United States
  • MedVadis Research Coorporation
    Waltham, Massachusetts 02451, United States
  • St. Louis Pain Consultants
    Chesterfield, Missouri 63017, United States
  • Healthcare Research Network
    Hazelwood, Missouri 63042, United States
  • Be Well Clinical Studies, LLC
    Lincoln, Nebraska 68516, United States
  • Synexus Clinical Research - Henderson
    Henderson, Nevada 89052, United States
  • AMR Las Vegas (Clinical Research Consortium)
    Las Vegas, Nevada 89119, United States
  • Albany Medical Center
    Albany, New York 12208, United States
  • AES New York
    New York, New York 10017, United States
  • Velocity Clinical Research - Cincinnati
    Cincinnati, Ohio 45242, United States
  • META Medical Research Institute
    Dayton, Ohio 45432, United States
  • NexGen Research
    Lima, Ohio 45805, United States
  • Clinical Investigations LLC.
    Edmond, Oklahoma 73034, United States
  • AMR Norman
    Norman, Oklahoma 73069, United States
  • Pacific Sports and Spine
    Eugene, Oregon 97404, United States
  • Velocity Clinical Research - Grants Pass
    Grants Pass, Oregon 97527, United States
  • Velocity Clinical Research - Providence
    East Greenwich, Rhode Island 02818, United States
  • Clinical Trials of South Carolina - Charleston
    Charleston, South Carolina 29406, United States
  • AES Dallas Forth Worth
    Dallas, Texas 75234, United States
  • Expert Pain
    Houston, Texas 77079, United States
  • Lubbock Spine Institute
    Lubbock, Texas 79410, United States
  • Be Well Clinical Studies - Austin
    Round Rock, Texas 78681, United States
  • JBR Clinical Research
    Salt Lake City, Utah 84107, United States
  • Velocity Clinical Research - Hampton
    Hampton, Virginia 23666, United States
  • AMR Norfolk
    Norfolk, Virginia 23502, United States
  • Velocity Clinical Research - Portsmouth
    Portsmouth, Virginia 23703, United States
08

References and documents

Publications

  • Siddiqui A, Xu JL, Abramowicz AE. Suzetrigine for the Treatment of Acute Pain: Comment. Anesthesiology. 2026 Feb 1;144(2):495-496. doi: 10.1097/ALN.0000000000005822. Epub 2025 Dec 11. No abstract available. PubMed 41384808 ↗

Individual participant data

Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2023 to primary completion in Oct 2024, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2023
First posted
Dec 19, 2023
StartActual
Dec 13, 2023
Primary completionActual
Oct 2, 2024
CompletionActual
Oct 16, 2024
Results delay requested
Sep 30, 2025
Last update
Oct 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06176196
Responsible party
Sponsor
First posted
Dec 19, 2023
Start date
Dec 13, 2023
Primary completion
Oct 2, 2024
Completion
Oct 16, 2024
Last update
Oct 1, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Suzetrigine

Start the discussion